Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
about
sameAs
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injuryOral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injuryRisk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisNew horizons and perspectives in the treatment of osteoarthritisThe safety of rofecoxibThe cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confoundingCurrent state of therapy for pain and inflammationCOX-2 chronologyDifferential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro studyPatients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of riskNon-steroidal antiinflammatory drugs and the risk of acute myocardial infarctionIs there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Cardioprotective aspirin users and their excess risk of upper gastrointestinal complicationsRisk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysisPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksProton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control studyThe coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risksCyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskCardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxibFactors associated with celecoxib and rofecoxib utilizationA comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an exampleNSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studiesClinical Pharmacology and Cardiovascular Safety of NaproxenRelative thromboembolic risks associated with COX-2 inhibitors.Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular functionSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksEtoricoxib: a highly selective COX-2 inhibitor.EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression.Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial.Evidence in practice--number 3: Cox 2 inhibitorsA cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospitalCost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Understanding the NSAID related risk of vascular events.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.
P2860
Q24186593-46E14D03-89B8-446E-938B-955D6F525897Q24240301-ADEF17F2-F7F5-4C20-A21D-3E466FE79E77Q24555478-0EC91D96-A907-4305-8D4D-E37496A1F158Q24657795-AD4CA76E-2FB2-4A1D-94F5-79D99FA5DF4FQ28176535-F7E4FE16-7C94-486C-B278-454BE3868850Q28177082-71CE3654-ACDF-4138-A354-B26D4BC2F79EQ28191916-1C393BD0-763E-479F-9788-C3BEB9F1EA0FQ28192719-8A379B74-B37E-4A24-A177-B812E2720D38Q28193949-B2F8A82A-6349-4147-8F27-185E4899C42DQ28195764-481249EF-BE3D-4DC0-B606-158286D06B75Q28196509-2B82083F-C495-4598-8AE0-2DABCDE394DBQ28196511-DB32AA29-4AC8-4775-8D67-7B1D8C0D915BQ28200511-6219A7EE-B426-4DC9-83FA-DB94F4092932Q28200524-EABFC700-A2EE-4443-878F-A54CFA91BB52Q28200569-F924F4F5-EBF6-45FA-A943-B9A138CB4754Q28200571-25965F1E-2B49-4B08-8A90-57B65920C091Q28211313-1CE3F2E8-69D6-4B0D-A0E6-A80257A99C69Q28219195-1CB8F41C-8C20-465B-842C-F246F73A7C80Q28219220-8538D10D-69A8-4FFC-9E50-8D93AEAFF0B9Q28222097-45467CF9-68D1-427C-8FF0-72F0C3AECDEAQ28238863-1388D3E4-87B2-4BC0-930F-6BE58F3139EDQ28472098-C2DCA0BA-E893-40D2-9FEB-C5D1BA48117FQ28742977-7FDA594E-6950-47DB-BC33-A797971B691FQ30360728-367B4C5B-4015-4092-B9BA-D3A73B22B80AQ30437125-50B5CDDE-19A4-4DBA-9A9C-DBB8C6FFCA5FQ30477135-6C411602-0603-4D23-AB94-B4AF24F930B6Q30629677-ABD87F40-66BC-4611-8FE9-7D94A28B1FE2Q33213983-E78B2939-F5DF-476E-9C2E-EAEF6E6FB96AQ33260652-CCB8FAC0-3A70-4ACD-909A-C59B8F6EACCEQ33323076-B3D63148-F783-4DED-BCD8-FEB9EDD281EAQ33367787-C62C3152-B176-4F45-9D33-9CDA8DF8CF56Q33701847-1A89918A-9201-44FC-9845-A9A28D036B03Q33722309-E720C4DC-15DA-4923-B4B9-0033936235AAQ34248051-87395E51-5B83-4A9B-B1E2-CBE43466D4C0Q34259503-49103337-D2DD-46B2-B830-D62A863ECCCCQ34384075-FE4E1E79-F987-4C2B-AE7A-BDF50E6049BEQ34449825-38EDBCBE-3397-4E33-836C-0F39382DF30FQ34546560-9156C749-8F8A-46BD-A7E9-881ADD233651Q34556831-FA402611-0C54-401A-B80A-E09C137DFE34Q34592340-00411648-7A3F-4819-8B6F-E44FBA4DF006
P2860
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Comparison of lumiracoxib with ...... s: randomised controlled trial
@ast
Comparison of lumiracoxib with ...... s: randomised controlled trial
@en
Comparison of lumiracoxib with ...... s: randomised controlled trial
@nl
type
label
Comparison of lumiracoxib with ...... s: randomised controlled trial
@ast
Comparison of lumiracoxib with ...... s: randomised controlled trial
@en
Comparison of lumiracoxib with ...... s: randomised controlled trial
@nl
prefLabel
Comparison of lumiracoxib with ...... s: randomised controlled trial
@ast
Comparison of lumiracoxib with ...... s: randomised controlled trial
@en
Comparison of lumiracoxib with ...... s: randomised controlled trial
@nl
P2093
P1433
P1476
Comparison of lumiracoxib with ...... s: randomised controlled trial
@en
P2093
Alberto Gimona
Bernhard Mellein
Christopher J Hawkey
Eduardo Mysler
Elena Ehrsam
Freek W A Verheugt
Gerd R Burmester
Gerhard Krammer
Howard Kirshner
James H Chesebro
P304
P356
10.1016/S0140-6736(04)16894-3
P407
P577
2004-08-01T00:00:00Z